CLINICAL radiology only a few years ago was confined to X-ray diagnosis and to X-ray and radium-chiefly gamma ray-therapy. Discovery of artificial radioactivity made available a new radiological tool for investigation, diagnosis and treatment of disease. Since 1935 various radio-isotopes have been used increasingly in the study of biological processes. By using the appropriate isotope it was shown that this method of investigation, in some ways better than classical chemistry, serves to shed light on the nature of physiological and pathological processes. Chemical analysis used as a clinical laboratory method provides qualitative and quantitative information about a condition at any given moment. Biochemical procedures do not provide information about the dynamics of digestion, assimilation and excretion, nor do they permit determination of the particular fraction of an end-product which results from material ingested two days previously, as compared with that which is present in the tissues from an earlier or later ingestion. The administration of elements which are physiological constituents in radioactive form overcomes these limitations of classical chemistry in elucidating processes of metabolism.
DISTRIBUTION STUDIES Some of the many studies of distribution ofradio-isotopes serve to illustrate the possibilities of the first line of investigation. Time does not permit of more than a brief sketch of those which have greatest significance for clinical radiology.
Phosphorus, which is a universal cell metabolite, is particularly suitable for studying distribution patterns within the body. A number of such studies have established that initial uptake of phosphorus is highest in liver, spleen, kidneys and bone-marrow. The longer the time interval between administration of P32 and observation of uptake, the greater the concentration in the skeleton. Parenthetically, studies have shown that turnover of P32 is higher by at least four times in growing epiphysis than in shaft. Tissues which metabolize slowly, on the other hand, such as fat, cartilage, and brain, show relatively lowest concentration of P32, and a differential concentration of P32 within the brain has been demonstrated, wherein the pineal body, the pituitary, and the hypothalamus concentrate most of the P32 which is taken up by the brain. Within cell aggregates such as leucocytes, it has been shown that almost all the P32 which is concentrated by the cells appears during the first forty-eight hours in the acid soluble fraction. After forty-eight hours increasing amounts of P32 are found in the nucleoprotein and phospholipid fractions, suggesting that enzymatic carrier systems are active in the transfer of phosphorus from acid soluble to nucleQprotein and phospholipid fractions. Studies of leukmemic blood, moreover, have shown that in myelocytes the nuclei concentrate appreciably more P32 than the cytoplasm, while in lymphocytes, concentration of p32 in nucleus and cytoplasm is about equal.
Certain studies of phosphorus distribution have been concerned with uptake in localized neoplastic tissue, as compared with normal tissue in the same subject. These investigations have illustrated clearly the preferential uptake of phosphorus by leukwemic and neoplastic tissues. The amount of uptake and the retention are dependent on the total phosphorus content of the tissues, on the rate of turnover within the tissue, and on the rate of growth of new tissue. The relatively high uptake of P32 by certain brain tumours has been utilized in localizing such tumours during surgery by means of probe counters inserted into the tissues.
The selective uptake of phosphorus by many tumours has been exploited in the preoperative diagnosis of such tumours by surface measurements where counts taken over the lesion and over comparable uninvolved tissue show differential concentration of radiophosphorus. In order to be investigated in this manner, lesions must of course be situated superficially-not more than 5 mm. beneath the surface of the skin. Many breast tumours and testicular tumours are so situated, and so are most suitable for diagnosis by surface measurement. The method has proved accurate in 89 % of malignant tumours of the breast, 91 % of benign tumours of the breast, 100% of inflammations, and 100% of seminomas. It is not suggested that the method be used to obviate surgical exploration. However, it is certainly of assistance to the surgeon to know in advance what sort of lesion he will encounter and whether the condition is complicated by the presence of inflammation. In addition, the method has the great advantage of permitting repeated examinations in order to follow the effect of a course of therapy such as hormone treatment, or radiation. Diminished concentration of p32 in the lesion indicates less active growth of tumour tissue.
The principle of surface measurement is useful also in localizing brain tumours preoperatively. In this procedure JIBi is linked to fluorescein to make the diiodofluorescein molecule which is selectively concentrated by brain tumour tissue. Measurements are made over the skull at various points.
Phosphorus, because of its ability to permeate red blood cells, has been used to measure circulating red blood cell volume. The procedure of labelling erythrocytes has been carried out with a number of different isotopes, including iron, and appears to be a more accurate method of blood volume determination than either dye or haematocrit methods. Sodium, which is chiefly an extracellular metabolite, provides a more accurate method of measuring extracellular fluid volume than either sucrose, sulphate, or thiocyanate. This method gives values of about 21 % of body-weight as sodium space, of which 15 % is plasma and 85 % interstitial fluid.
The observation that the concentration of radiosodium in pleural and ascitic fluids is essentially the same as in blood serum affords a useful means of estimating the volume of excess extracellular fluid in patients, by comparing sodium space values for such patients with values for normal subjects of equal body-weight. Radiosodium has been used successfully in the localization of placenta. Counts made over the abdomen following a dose of Na24 will indicate the position of the placenta. The procedure may become important in the localization of placenta prvvia.
A major subject of distribution study has been the concentration of iodine by the thyroid gland. It was early established by largely qualitative methods that thyroid concentrates iodine in accordance with its degree of function and hence of its need for this metabolite. Normal subjects were shown to reach highest uptake approximately two days after administration of a test dose. Patients with non-toxic goitre and normal B.M.R. showed uptake 10 to 12% higher than normal subjects. Patients with thyrotoxicosis showed highest uptake about one to four hours after administration of radioiodine, and they showed a rapid decrease in radioiodine content so that two days after administration often only about 5 % of the administered dose remained in the gland. Patients with hypothyroidism without goitre showed exceedingly low uptake and exhibited [curves without any true peak. In thyroiditis uptake was very low, and in hyperplastic tissue uptake was higher than in involuted tissue.
For the most part patients with thyroid carcinoma show very low uptake. Histological studies of thyroids of a group of such patients compared with radio-autographs demonstrated that structure of the tumour tissue is a determining factor in the ability to collect radioiodine. Orderly cell arrangement in follicular pattern and presence of colloid material are essential to radioiodine uptake in both primary and metastatic tumours. It has been shown that during the first three days after administration radioiodine is concentrated in the cells and subsequently it is found in the colloid. Much thyroid tumour tissue, however, is heterogeneous in structure and this accounts for non-uniform uptake in many thyroid tumours. Accordingly a single biopsy cannot be relied upon as being representative of radioiodine uptake throughout the tumour.
It was hoped that differences in capacity of thyroid tissue to concentrate radioiodine would constitute a possible means ofestablishing differential diagnosis ofthyroid disease. In practice, however, experience has shown that there are no clear-cut patterns of uptake and retention, and overlapping has been observed between groups of euthyroid subjects and patients with thyrotoxicosis on the one hand, and between euthyroid subjects and patients with myxcedema on the other.
While the distribution of a metabolite isotope as determined by uptake study is of great significance for determining the avidity of certain tissues and organs for the metabolite, such findings in most instances do not reveal anything about the mechanism of organ or tissue function.
These considerations have especially important bearing on our second general topic of discussion, namely, investigations of the mechanism of metabolism and organ function by means of radio-active isotopes.
INVESTIGATION OF MECHANISM OF METABOLISM AND ORGAN FUNCTION
Radiophosphorus has been used to study phospholipid metabolism. Animal experiments have established the rate of turnover of phosphatides and have shown that the synthesis of phospholipids is primarily a function of the liver. Plasma phospholipid concentration is thus a measure of liver function in this regard. Test doses of radiophosphorus have been administered to patients with hyperlipemia and the rate of appearance of phospholipid in the plasma has been determined. It was found that, irrespective ofthe cause ofhyperlipaemia, a high phospholipid plasma level indicated overproduction of phospholipid by the liver rather than accumulation due to biliary obstruction or to decreased breakdown of the phospholipid molecules by the tissues. The effect of choline and methionine on phospholipid production has also been studied in patients with cirrhosis of the liver. P32 administered intramuscularly was used as an indicator. It was observed that a single large dose of either choline or methionine produced an increase in the rate of turnover of phospholipid in these patients. No such increase in turnover rate occurred after protracted administration of methionine, or after administration of a single large dose of choline following protracted treatment with methionine. This suggests that increased turnover following a single large dose of either choline or methionine reflects a relative deficiency of lipotropic agents. The degree of response is probably an indication of the value to be anticipated from treatment of cirrhosis with lipotropic agents. It seems worth while pointing out the fact that isotope technique has contributed knowledge of a significant character to the intricate problem of liver function.
Administration of radiosodium to human subjects in shock from severe burns shows increased sodium space without commensurate increase in body fluid, and at the same time there is a disappearance of sodium from the urine. Such observations suggest that the antisodium barrier between intracellular and extracellular fluids has been affected and that sodium is infiltrating tissues where it does not normally go. Thus certain parts of the body are deprived of their normal sodium supply. Based on this knowledge it has been found that 13 treatment of patients suffering from severe burns with sodium lactate solution is remedial. Apparently administration of sodium in this form by infusion or orally serves to re-establish fluid balances and to maintain blood volume and blood pressure.
Radioiron has also been used in studies of shock to measure stagnation of blood cells. Widespread stagnation of red cells was demonstrated by the radio-isotope method, and was related by the investigators to mean arterial pressure since it had been shown to be independent of blood loss. This in turn suggested the desirability of introducing red cells in transfusions as well as plasma, in order to avoid starvation of parenchymal cells due to stagnation.
I have referred earlier to the general patterns of uptake of radioiodine by the thyroid gland. The clinical usefulness of these observations, however, depends upon linking the utilization of iodine to thyroid function, and for this, more complete investigation of the dynamics of iodine metabolism is needed. Radioiodine has two uses in clinical radiology-one as a means of delivering therapeutic amounts of radiation to the thyroid, and second as a means of distinguishing among various disorders of thyroid function. Early efforts to use radio iodine as a diagnostic tool were somewhat disappointing due to two fallacies, namely, that thyroid function could be determined by a simple measurement of degree and rapidity of uptake of radioiodine by the thyroid gland, and that biological material might be counted on to behave in a wholly consistent and homogeneous manner. That the second idea is a misconception is clearly demonstrated by the considerable overlapping in uptake values which occurs between euthyroid and thyrotoxicosis and myxcedema groups.
Refinement of technique has shown how much more can be learned concerning thyroid function than was possible by gross measurement of uptake at arbitrarily fixed intervals, together with determination of radioiodine excreted over the same period.
Although the percentage hourly uptake, the half-peak uptake, and the maximum uptake are valuable indicators of the avidity of the thyroid gland for iodine, no one of these values alone reflects the physiology of the gland which is a time-related function. It is obvious therefore that in every case the entire process of concentration and release of iodine must be known. There is unfortunately no short cut to the attainment of this knowledge. The function of the thyroid gland is the production of thyroxine which is released into the circulation as protein bound iodine. Thus the determination of protein bound radioiodine in the plasma is an essential clue to thyroid function. The total radioiodine plasma level is a measure of inorganic and protein bound iodine and so is not definitive concerning thyroid function. Similarly, a high clearance rate of radioiodine from the plasma together with normal excretion is an indication of thyroid avidity for iodine, but only subsequent determination of protein bound iodine will demonstrate the ability of the thyroid to convert the inorganic iodine, which it has collected, into thyroxine.
These considerations make clear the fact that the more facets of investigation are used, and the more the concept of a dynamic flux is kept in mind, the more nearly we shall succeed in narrowing the margin of error which exists in attempting to distinguish among various thyroid disorders by means of radioiodine. Nevertheless, we shall always find that the unavoidable variability of biological material tends at times to confuse the issue and to cloud certain of our results. For this reason it seems wiser to regard radioiodine as one very valuable tool for the investigation of thyroid disease which, when combined with protein-bound iodine determinations, B.M.R. studies, galactose-tolerance tests and other standard procedures, may serve to bring even borderline cases into the focus of correct diagnosis. THRPY Radio-isotopes are tools for the treatment of certain pathological conditions. Applied topically they constitute easily controlled sources of radiation, similar in effect to X-rays and radium. As internally administered agents their therapeutic effect depends on the biochemical role of the element or compound which contains radioactive atoms. Tissues, organs and organ systems concentrate metabolites selectively in accordance with their requirements and irrespective of the radioactive properties of the metabolite, so that a therapeutic effect can be attained if a tissue is capable of concentrating a particular radioisotope in adequate amount to deliver the desired dose of radiation. This fact, while it opens the way to employing a number of metabolites in radioactive form as therapeutic agents, at the same time accounts for certain limitations in the use of these materials.
The primary objective of all radiation therapy is the destruction of pathological tissue and the preservation of surrounding healthy tissue. It will be readily appreciated that the margin between the requirements of diseased and normal tissue for a certain radiometabolite may be too narrow to permit of a radiation dose sufficient to destroy the pathological tissue without undue damage to normal tissue.-A case in point is the high uptake of strontium by both normal bone and osteogenic sarcoma. It is not possible to avoid radiation damage to bone and bone-marrow when it is attempted to destroy osteogenic sarcoma by means of radiostrontium. In the case of more ubiquitous metabolites such as phosphorus and. sodium, one must have in mind the effect on the whole body of administering therapeutic amounts of these substances in radioactive form.
Again because of their biochemical role, radio-isotopes remain in the body for varying lengths of time, and of course they continue to deliver radiation until they are eliminated or until their radiological decay is complete. In this respect they differ from external or topical irradiation in which the ionizing action continues only as long as the radiation source is applied.
Nevertheless, radio-isotopes are substantiating in increasing measure the early hope entertained for them. With improving knowledge of biochemical processes and of the biological effects of radiation, some of the radio-isotopes are being applied more effectively to certain pathologicaI conditions. In a few instances they seem to offer better results than any other therapy.
As in any method of treatment, however, there are contra-indications as well as indications for the use of radioactive isotopes. In topical use where they either replace or act as adjuncts to X-rays and radium, no question arises concerning their applicability. For systemic use the radio-isotope must be judged for suitability by its physical and biochemical properties in relation to the pathological condition to be treated. In addition consideration must be given to the unavoidable exposure of healthy tissue to radiation and the immediate danger of untoward effect upon such tissue; and more especially one must keep in mind the possibility of late radiation damage.
Beta or gamma radiation from isotopes is utilized in topical application. Topical use includes surface application to the skin, implantation into tissues, infiltration of tissues, and intracavitary administration.
The effect of beta radiation on the skin has long been known. Beta particles have a finite range directly related to their energy, and they can penetrate skin to a depth of a few millimetres or even centimetres. Before the discovery of artificial radioactivity the sources of beta radiation were natural radioactive substances and cathode ray tubes. Neither of these sources provides pure beta or electron radiation. -vfany artificially radioactive substances provide pure beta radiation. Beta radiat'on from P32 has been shown to produce varying degrees of erythema, dependent on exposure. Based on this obstrvation a technique has been developed for the treatment of such superficial skin lesions as basal-cell and squamouscell carcinoma, hyperkeratosis, and hamangioma by local application of p32. Radioactive disodium-acid-phosphate of known activity is soaked into blotting paper discs of known dimensions, and dried. These discs can then be applied over any surface of the skin, held in place by adhesive tape, and kept in place for a period calculated to deliver the desired radiation dose. Exposure time is calculated in microcurie hours per square centimetre or surface rep. Calculations and measurements have shown that one microcurie per hour per square centimetre dissipates energy equivalent to approximately five rep. in the first millimetre of tissue. Measurements have also shown that 49 % of the total radiation from a P32 plaque is absorbed in the first millimetre of tissue and the absorption is practically exponential.
While from the physical point of view the planimetric dose estimation may be correct, from the biological point of view, estimation of the total accrued energy in the tissue mass as a whole is more representative because it-has been shown that the acute reaction of-tissues is both sharply confined and uniform to a depth of 5 mm.
This method of treatment has resulted in destruction of superficial basal-cell and squamouscell carcinomas in 94 % of cases treated. It is particularly effective on curved surfaces where a homogeneous distribution of X-rays is impossible. It is valuable also in the treatment of hemangiomas of the "strawberry type". It is not considered advisable for "port-wine type" hemangiomas, or for deep-seated cavernous angiomas.
Strontium 89 is a beta radiator with similar radiation characteristics to P32, and has proven of value in the treatment of superficial skin and ocular lesions.
A number of localized neoplasms amenable to intracavitary and interstitial irradiation with radium and radon have recently been treated with various radio-isotopes.
The isotope which seems in many ways to be the most promising for intracavitary and interstitial irradiation is radiocobalt.
The radioactive properties of radiocobalt make it a highly suitable source of external and interstitial radiation. It may be said to have as its only disadvantage a shorter half-life than radium, but it offers the following important advantages: (1) it emits low energy beta radiation-which can be screened easily-80 mg. per square centimetre silver stops beta radiation from Co entirely; (2) the gamma radiation is almost homogeneous-I1 and 13 Mev.
Proceedings of the Roydl Society of Medicine photons are emitted; (3) no contamination occurs due to gaseous daughter-products; (4) there is rapid elimination of any Co which might enter the body; (5) Co is available in any desired quantities at a cost far below that of radium; (6) Co can be prepared in any shape and form and can be electroplated on any material and activated subsequently for clinical use; (7) Co is readily soluble and so may be used in solution in thin-walled containers for intracavitary use.
Flexible radiocobalt wire in nylon threads, and radiocobalt needles have been used successfully for interstitial radiation therapy. Recently dose calculation tables similar to the Paterson-Parker radium dosage tables have been prepared.
Radiocobalt beads have been used for intracavitary irradiation at the University of California for malignancies of the maxillary sinus, nasopharynx, urinary bladder, and uterine body cavity. Beads of 3 and 5 mm. diameter were activated to strengths of 0-6 to 6-0 millicuries for small beads, and 10 to 200 millicuries for larger beads. The beads were silverplated to a thickness of 80 to 130 mg. per square centimetre. The beads were calibrated by the United States Bureau of Standards in roentgens per hour at 1 cm. Beads were used in preference to needles in order to approach more closely point sources of radiation. A Foley or Foley-Alcock catheter is used to hold the bead which is placed in the central channel in such a way that when the Foley bag is inflated the bead is in its centre. In this manner equidistant distribution of radiation is ensured. A deflated Foley bag is inserted into the cavity to be treated. The catheter is then inflated with an iodide solution. From the amount of fluid required to inflate the catheter the distance between the cobalt bead and the cavity wall can be determined and the radiation dose calculated. The dose is expressed in gamma roentgens at the wall of the cavity and at various depths. The dose is approximately radially uniform on all surfaces. Dose determination is based on phantom measurements and calculation of absorption in matter of electron density of soft tissues.
Doses of 6,000 to 8,000 r in five days have been tolerated without untoward reaction in cases of maxillary sinus and nasopharyngeal tumours. Tumour doses of 5,000 to 7,000 r in four to five days, and repeated after four weeks, have been well tolerated both in the acute post-radiation phase and during the three-year observation period, in tumours of the bladder.
The radiocobalt method appears to be superior to any other form of radiation therapy for treatment of bladder tumours. It is also preferable to fulgurization of multiple papillomata of the bladder. The effectiveness of this method in uterine body tumour is still undetermined.
In general the effect of radiocobalt on tumour and surrounding tissue is comparable to that of radium.
The use of radiocobalt at a distance for telecobalt therapy has been suggested, but anv advantage of this method over a one or two Mev. X-ray radiation-beam-unit appears to be questionable.
Radiosodium and radiocobalt in solution have been used in special Foley catheter-like balloons for irradiation of bladder tumours. Clinical results are promising, but the method is beset by problems which tend to restrict the usefulness of this technique. The effect of high energy beta radiation from Na24, the complex problem of dosage calculation, and the mechanical problems of dealing with an isotope in liquid form in this procedure, all constitute limitations of the method.
The radio-isotope of zinc, Zn65, has a half-life of 250 days. It has been shown that zinc is taken up rapidly by the liver and spleen and is rapidly lost from these organs. Radiozinc in colloidal form when infused intraperitoneally is known to remain in the peritoneum without diffusion for several hours. Based on these facts, radiozinc has been used experimentally in the treatment of advanced ovarian carcinoma. In some cases marked improvement and loss of ascites has followed this treatment. Similar results have been reported for the treatment of liver metastases of melanosarcoma with colloidal radioactive chromic phosphate. Radiogold has also been used in the treatment of inoperable ovarian malignancies, by tumour infusion, and improvement of the patients has resulted. The danger of this type of therapy is due to the large volume of tissue which is irradiated locally. The possibilities of local necrosis due to beta radiation, and in the case of radiozinc, the total body effect of gamma radiation, dictate a very conservative course in this type of therapy. The case for infiltration of tumours with radiogold is not well founded moreover, because the same treatment can be carried out with X-rays or radium, both of which permit more accurate calculation of dosage.
Only three radio-isotopes have so far proved their value in systemic radiation therapy. These are radiophosphorus and radioiodine, and to a lesser extent, radiosodium.
The use of P32 in chronic granulocytic and chronic lymphoid leukaemia and in polycythemia vera is based on experimental findings that p32 in sufficient quantity has a depressing effect onhlmatopoiesis, and that phosphorus is selectively concentrated by bone, bone-marrow, leukxamic and neoplastic tissues.
Radiophosphorus in the form of isotonic disodium-acid-phosphate administered intravenously is well tolerated. Oral administration is less satisfactory because of interference 668 16 with absorption by processes of ingestion, the higher rate of excretion, and the difficulty in relating the dose administered to the dose retained.
In chronic granulocytic leukaemia a hxmatological remission is frequently produced with radiophosphorus and this may last several months or as much as a year. In doses of 0 5 to 2-0 millicuries, P32 does not cause radiation sickness. With larger doses, however, radiation sickness does occur. Splenomegaly, hepatomegaly, and lymphadenopathy decrease gradually under P32 therapy during early stages of the disease and they may disappear entirely within about four weeks of instituting treatment. In later stages of the disease the response is less satisfactory. In the terminal stage, P32 is just as ineffective as any other radiation therapy and impairs rather than benefits the patient's general condition.
In chronic lymphoid leukxmia the response to P32 iS, in general, similar to that in chronic granulocytic leukxemia. Complete remissions are less frequently seen in chronic lymphoid leukemia, and remissions which do occur are of shorter duration for the most part.
A certain lack of agreement exists with regard to the extent to which treatment of chronic leukxmia should be carried. Some clinicians believe that when the white blood cell count is brought down to about 50,000 no further treatment should be given until exacerbation of the disease process becomes evident through increased white cell count, enlargement of liver, spleen and glands. A more reasonable approach would seem to be to continue treatment in the first instance until the blood count is brought as near normal as possible. Erythropoiesis is of paramount importance in determining extent of treatment and the presence of pathological white cells in the peripheral circulation is of greater significance as a criterion of remission than the total leucocyte count. A complete remission in leukemia is attained when the diagnosis cannot be made from the blood count or smears. It is not always possible, of course, to attain a complete remission. In cases of long duration especially, it is observed that attempts to bring the white cell and differential counts within normal limits are accompanied by depression of erythropoiesis. In such cases one must be satisfied with a partial remission. When a relapse occurs after remission, treatment is re-instituted, with the intent of bringing about another remission. An increase of total white cell count by more than 15,000, together with increase of primitive cells in peripheral blood, and increase in size of liver and spleen, are considered indications for resuming treatment. Increase of B.M.R. may precede these clinical manifestations by several weeks; its determination is therefore of great value in evaluating a particular case.
Certain investigators take the stand that radioresistance develops characteristically in leukemia and in related disorders, due to radiation therapy. It is true that larger doses of radiation and more frequent treatment become necessary as the disease progresses. Finally even large doses of radiation fail to stem the progress of the pathological process. The gradual increase of primitive cells in bone-marrow and peripheral circulation, the progressive displacement of erythropoietic and megakaryocytic elements, and the natural history of the disease in treated and untreated cases, suggest very strongly the probability that increasing activity of the malignancy and not "radioresistance" is the cause of lessened response to radiation therapy. The complete lack of response in acute leukaemia would seem to substantiate this view.
Radiophosphorus has been completely unavailing in the treatment of any type of acute leukxemia.
In chronic leukaemias haematological response can be produced with single doses of from 2-0 to 6-0 millicuries of P32. Experience has shown, however, that a closer control of dosage can be exercised by the administration of small doses of 0 5 to 15 millicuries at frequent intervals. In this way a radiation level appropriate to the condition can be maintained.
Several patterns of fractionation are now in general use in the treatment of chronic leukamia.
These are (1) Simple saturation method consisting of one 2 to 3 millicurie dose followed by small doses to adjust the radiation level for excretion and decay; (2) fractional saturation method wherein an initial small fraction is followed by similar fractions every second or third day until the desired radiation level is attained. This level may then be maintained by additional fractions. UJsually the initial dose is 500 microcuries, and subsequent fractions do not exceed 1,500 microcuries. This method has the advantage of a more gradual approach to the ultimate radiation level. Moreover the effect of the initial doses may give an indication of the response and tolerance of the patient to P32, and thus will provide a means of determining what radiation level will be required; (3) thefractional method consisting of equal fractions of 1 to 1-5 millicuries at intervals of one or two weeks. Treatment is continued until the desired effect is attained.
The involved nodes in lymphosarcoma have been shown by tracer studies to concentrate radiophosphorus to a relatively high degree. This fact constitutes the rationale for treatment of this condition with P32. Results reported from different centres, however, show variable effectiveness of the treatment. Some cases of lymphosarcoma make a satisfactory temporary response to P32 therapy. Regression of enlarged nodes, disappearance of ascites and other clinical signs have been observed. Lymphosarcoma is a protean disease and the variability of results of P32 treatment may be explained by the fact that P32 uptake by involved glands is very variable. It is necessary to carry out uptake studies on patients with lymphosarcoma before instituting P32 treatment. If uptake is high it is probable that P32 will give some temporary benefit. If it is low, neither P32 nor X-ray will produce any benefit.
The same considerations apply to Hodgkin's disease, mycosis fungoides, and multiple myeloma. If P32 is employed in the treatment of any of these diseases, careful fractionation of dose will prevent the occurrence of anemia, leucopenia, and thrombocytopenia. However, in general I do not advocate P32 in the treatment of these conditions except in selected cases.
In polycythemia vera it is now the general consensus that P32 is the treatment of choice. The method of treatment now in general use is the intravenous administration of 5 to 6 millicuries in a single dose. Six to eight weeks later this may be followed by a second similar dose depending on the himatological picture at that time. In some cases a single dose produces a complete remission. More often two doses of equal size are necessary, and, rarely, a third dose three months after the first is required.
A minor modification of the single large dose technique consists in dividing the dose into two or three equal fractions which are given on succeeding days. In this way less P32 iS lost by excretion, and radiation sickness is avoided.
Hmematological response to P32 treatment may not be anticipated in polycythaemia vera for four to six weeks and it may be delayed as much as three months. This latent period is of course due to the long life-span of erythrocytes. Radiophosphorus apparently affects only erythroblasts and therefore the effect of treatment becomes evident only when erythrocytes which would have resulted from these erythroblasts fail to appear in the circulation.
The question has been raised whether P32 is more likely than other forms of therapy to result in the development of leukiemia in patients with polycythemia vera. Myelogenous leukaemia is known to be a frequent complication in either treated or untreated polycythwmia vera. There are many examples in the literature of development of leukiemia in polycy-th2emia patients whose only treatment was phenyl-hydrazine, Fowler's solution, or venesection. A more reasonable explanation of incidence of leukamia in polycythtmia patients who have been treated with P32 iS that any polycythaemia patient who does not succumb to cardiovascular accident or disease will terminate in leukxmia. Radiophosphorus produces longer and more complete remissions of polycythiemia vera than other forms of treatment, and so prolongs the life of the patient. This may result in the incidence of more deaths from leukaemia as a natural terminal development of the disease, wholly unrelated to treatment with P32.
Evaluation of the dose effect relation when P32 is administered internally requires information concerning energy dissipated in various tissues. Marinelli, Evans, Mayneord, Bush and others have developed formule for calculation of energy accrued by the tissues due to a single dose of P32. According to these calculations-1 -microcurie P32 destroyed per kg. body-weight = i rep. 1 microcurie P32 uniformly distributed in a subject weighing 70 kg. will deliver 0-6 rep or grm.r/grm. in twenty-four hours.
These calculations apply only to a biologically inert system, since they assume uniform concentration and retention to complete decay of the dose administered. Experimental evidence shows, however, that phosphorus is not uniformly distributed in the body. On the contrary there is constant flux due to exchange and interchange of the metabolite among various tissues, as well as the daily loss due to excretion. There is no method yet known whereby the biological flux of phosphorus in the body can be measured. The rate of clearance from blood,. excretion in the urine and faeces can of course be measured. From the amount lost by excretion, the total amount remaining in the body at any given time can be calculated.
The distribution of p32 in various body tissues is known from biopsy and autopsy studies. In general bone shows the greatest avidity for phosphorus, and is followed in order by spleen and liver. Within six to twenty-four hours after the administration of single or multiple test doses of 4 to 9 microcuries per kg. body-weight, when the P32 is given in the fotm of Na2HPO4, concentration in liver, spleen and bone is four to six times greater than in muscle, fat and skin.
After seventy-two hours, concentration in bone, spleen and liver is six to ten times that in muscle, fat, and skin. At certain intervals the concentration in bone and spleen and liver may differ, but the uptake in these tissues is always of the same order of magnitude, and, taken together, is about six to ten times as great as in all other tissues. Bone, spleen and liver, which for convenience we may designate "the bone compartment", constitute 10 to 12% of the body-weight. These tissues are all affected by anything which affects the hmmatopoietic system. The dose-effect relation can be evaluated only if the dose estimation is based on the differential distribution of the retained amount of the isotope. Following determination of the retained amount of P32 it is assumed that after the equilibration period of three days, a 10 to 1 ratio is established between the bone, spleen and liver compartment, and the muscle, fat, and skin compartment. These assumptions may be subject to certain theoretical criticisms. First, the 10 to 1 ratio represents a maximum rather than an average. In clinical practice, however, it is advisable to use such a maximum since it ensures safety against damage of haematopoietic system. A second criticism may be made of the assumption of the existence of a 10 to 1 ratio on the third day, since actually the ratio is reached gradually over a longer period. Again in practice, however, this error is negligible and would not justify undertaking the very complex mathematics required for precise determination of the ratio on each day.
The advantages of this method of dose estimation are first, that it takes into account the factors which characterize an active biological system; second, it gives a better indication of accrued energy within the tissues; third, it affords a better correlation of the physical dose with the biological effect; fourth, it provides greater insurance against excessive irradiation; fifth, it affords a sounder basis for the comparison of radiation doses from X-rays and radio-isotopes.
Without entering into the details of dose calculation by this method, it must be emphasized that the weight of the patient is a primary factor in establishing the bone compartment-soft tissue compartment relation. For clinical use four dose record forms have been devised to cover patients in the weight range of 40 to 90 kg., with appropriate correction factors for ages falling within four major groups. From the dose rate figures the daily and cumulative soft tissue and bone compartment dose can be calculated, as well as the total body integral dose. Due to the difference of concentration ratio the energy accrued in the bone compartment is nine times greater than that in the soft tissue compartment.
This method of dosage estimation places radiophosphorus therapy on a firmer basis, and provides a means of correlating external and internal radiation therapy.
The radio-isotope which has attained greater prominence as a therapeutic agent during the post-war years is radioiodine. The first experimental attempts to treat hyperthyroidism with 1131 were reported in 1941-42. It was not until after World War If, however, that carrier free f131 became available in abundance and radioiodine therapy of hyperthyroidism became widespread.
Many hundred cases have been reported in the literature, and various plans of treatment have been advocated. Review of the literature offers abundant evidence that radioiodine is an effective means of producing remissions in hyperthyroidism.
Investigators at the Ufniversity of California Hospital have analysed their results in 100 consecutive cases treated between September 1945 and October 1949. Of the 100 patients 89 received what was considered a complete course of J131 therapy. 13 patients were men and 87 were women. 24 patients were under 25 years, 58 were between 26 and 50 years, the remainder were over 50 and 3 of these were over 65 years.
Of the 100 patients 49 had had one or more kinds of treatment for thyroid disease (12 surgery, 29 Lugol's, 11 propylthiouracil, 7 thiouracil, 3 X-rays, 9 thyroid by mouth).
Of the 89 patients who received full courses of treatment, 84 were considered clinically well. Reports reflect decrease in size of thyroid to normal; return of B. M.R., protein-bound iodine, cholesterol, and galactose tolerance to normal; normal uptake of radioiodine by the thyroid gland restored. 5 of the 89 patients developed hypothyroidism and are under treatment for that condition, 8 patients developed mild hypothyroidism but they do not require specific medication. 3 patients are receiving thyroid medication for exophthalmus.
This analysis is typical of reports from other centres. All reports contain some reference to initial exacerbation of disease following radioiodine therapy, and to incidence of hypothyroidism amounting to about 7 to 10O% of all cases treated.
There is no uniformity in the dosage used in radioiodine treatment of hyperthyroidism, nor with regard to the number of treatment courses which may be given. In the various centres, doses have ranged from 2 to 29 millicuries, and the number of courses has varied from one to four.
Attempts have been made repeatedly to calculate the dose in terms of energy accrued by the thyroid gland. Such calculation is possible only if the following points are ascertained: Weight of the thyroid gland, distribution of the isotope within the gland, total amount of the isotope decayed in the gland. In clinical practice it is justifiable to make the following assumptions: that the weight of the thyroid gland is known, that distribution of the isotope within the gland is uniform, that all beta particles are utilized within the thyroid gland. Actually the amount of I131 which decays in the gland can be determined from the uptake curve. In some instances the loss of iodine from the gland is at a constant rate representing an effective half-life of the isotope within the gland. Since there is a wide spread of effective half-life in different patients, it is important to determine the EHL for every patient. This requires that an uptake study be carried out for a period of four or five days to demonstrate collection and release of iodine by the thyroid.
At the UJniversity of California Hospital at present the amount of f131 necessary to deliver 6,000 r to the thyroid gland is calculated from the uptake curve for the test dose and from the thyroid weight. This amount is given as an oral dose. Since the uptake curve for the therapy dose may vary from the one obtained for the test dose, a complete uptake curve is made for the therapeutic dose. On the basis of this curve the radiation received by the thyroid gland is recalculated. Six weeks after the initial treatment dose an uptake curve is made with a test dose of 1131. If necessary the patient is re-treated and the dose is determined as before. About twelve weeks after initiation of therapy an uptake curve is made again after a test dose and therapy is given if indicated.
One important factor in successful treatment with 1131 is the selection of cases. It is now generally accepted that only patients with diffuse hyperplastic glands should be treated.
Patients with nodular goitres should not be treated with radiation. It is generally felt, also, that patients should be above 45 years, because of the theoretical possibility of late malignancy as a result of radiation.
Radioiodine was widely adopted for the treatment of hyperthyroidism on the premise that its use would obviate the problems encountered in X-ray therapy. These are, of course, skin erythema, reaction on the laryngeal mucosa, initial exacerbation of disease symptoms, and development of myxcedema. With the exception of skin effects every one ofthese reactions is known to occur with 1131. Moreover, when X-ray therapy is applied skilfully these sequele can be avoided. The results of external radiation therapy of hyperthyroidism compare favourably with the results of any other method of treatment. Also it must not be forgotten that with radioiodine the whole body is subjected to some radiation, though, with the dosage levels used in the treatment of hyperthyroidism, it must be admitted that no untoward haematological effects have been observed in patients who have been followed for a five-year period.
As we have observed previously, functioning thyroid tissue only concentrates iodine. For this reason relatively few forms of thyroid carcinoma are amenable to J131 treatment. Benign metastasizing struma with orderly follicular arrangement and'presence of colloid has been shown to concentrate iodine to an appreciable degree. However this condition constitutes only about 15 % of all neoplastic thyroid lesions. Wherever function can be stimulated in non-functioning thyroid tissue 1131 can be used with remedial effect. This knowledge has been useful in treating metastases from thyroid carcinoma with f131 and a variety of methods have been used to stimulate thyroid function. Thiese include propylthiouracil, thyrotrophic hormone, surgical and radiological removal of the thyroid gland. The presence of functioning thyroid metastases may be demonstrated by surface measurements over the lesions, following a test dose of 1131. If such measurements indicate function, therapeutic amounts of 1131 can then be administered. The literature contains reports of treatment of such cases with temporary benefit. In general, doses used in the treatment of thyroid carcinoma must be several hundred times larger than those used in hyperthyroidism. However, no pattern of dosage for thyroid malignancies has been suggested. At the UJniversity of California Hospital 64 patients with neoplastic thyroid disease have been studied for uptake of 1131. Only 3 of the patients showed sufficient uptake to justify a therapeutic trial. Attempts to stimulate function in thyroid carcinoma were all unavailing. Two of the patients who were treated received 500 and 600 millicurie doses respectively. The total doses in both cases were given in individual doses of 100 millicuries at intervals of one month. The patients became profoundly myxoedematous. In one patient a mass in the pharynx disappeared under treatment, but biopsy showed that tumour was still present in the area where the mass had been. The other patient showed no regression of multiple pulmonary metastases. Although some dramatic improvements have been reported from the treatment of thyroid carcinoma with I131 it is clear that the efficacy of this therapy is far from established.
It is my hope that in this brief review of radio-isotope research I have been able to show that artificial radio-isotopes have an established place in clinical radiology. No longer may we think of them simply as a means of experimentation. In the hands of radiologists the isotopes have an acknowledged place in the diagnosis and treatment of disease. It would be quite wrong, however, to suppose that in the radio-isotopes we have found the answer to all our diagnostic and therapeutic problems. Rather, through proper understanding of their nature and their biological effects, which subjects are the particular province of the radiologist, radio-isotopes may increasingly take their place as one important tool among the various tools which the radiologist already has at his disposal.
